Hong Kong digital marketing service provider PressLogic (PLAI.US) plans to price its IPO at $4-6 per share, aiming to raise $9 million.
This company operates digital marketing services in Taiwan Province and Hong Kong. Its content marketing solutions include a digital marketing solutions section, which includes content editing, influencer marketing, and display advertising, as well as a display banner section, including direct and programmatic advertising.
Hong Kong digital marketing service provider PressLogic announced its IPO terms on Tuesday, with the company planning to issue 1.8 million shares at a price of $4 to $6 per share, raising $9 million.
Based on the midpoint of the proposed price range, PressLogic's market value will reach $83 million.
The company operates digital marketing services in Taiwan and Hong Kong. Its content marketing solutions include a digital marketing solutions segment, which includes editorial content, influencer marketing, and display advertising, as well as a display banner segment, including direct and programmatic advertising.
As of the date of the prospectus, PressLogic operates 9 proprietary media brands with over 12 million fans and subscribers, including 9 websites, 5 applications, 11 Facebook fan pages, 11 Instagram profiles, and 8 YouTube channels.
PressLogic was founded in 2016 and had revenue of $15 million for the 12 months ending on June 30, 2025. The company plans to list on Nasdaq under the ticker symbol PLAI. American Trust Investment Services is the sole book-running manager for this transaction.
Related Articles

Smart flying golden Thai(688443.SH): Celltrion's monoclonal antibody injection included in the 2025 National Medical Insurance Catalog.

HaiChuang Pharmaceuticals (688302.SH)Daon Zalu Amin soft capsules have been included in the 2025 National Medical Insurance Drug List.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH)Innovative drugs Avimeplanib and Golirelin included in the new version of the national medical insurance directory.
Smart flying golden Thai(688443.SH): Celltrion's monoclonal antibody injection included in the 2025 National Medical Insurance Catalog.

HaiChuang Pharmaceuticals (688302.SH)Daon Zalu Amin soft capsules have been included in the 2025 National Medical Insurance Drug List.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH)Innovative drugs Avimeplanib and Golirelin included in the new version of the national medical insurance directory.






